Clinical Trial Update: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs) [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluates the efficacy and safety of CSL222 (etranacogene dezaparvovec) gene therapy for adults with Hemophilia B who have pretreatment AAV5 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• CSL222 (etranacogene dezaparvovec) (etranacogene dezaparvovec)

Snippet

Sponsor: CSL Behring | Conditions: Hemophilia B | Phase 3 | Status: RECRUITING